These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38515840)

  • 1. Assessing the relative contribution of CYP3A-and P-gp-mediated pathways to the overall disposition and drug-drug interaction of dabigatran etexilate using a comprehensive mechanistic physiological-based pharmacokinetic model.
    Udomnilobol U; Dunkoksung W; Sakares W; Jianmongkol S; Prueksaritanont T
    Front Pharmacol; 2024; 15():1356273. PubMed ID: 38515840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potentially Significant Role of CYP3A-Mediated Oxidative Metabolism of Dabigatran Etexilate and Its Intermediate Metabolites in Drug-Drug Interaction Assessments Using Microdose Dabigatran Etexilate.
    Udomnilobol U; Jianmongkol S; Prueksaritanont T
    Drug Metab Dispos; 2023 Sep; 51(9):1216-1226. PubMed ID: 37230768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Eur J Pharm Sci; 2021 Oct; 165():105932. PubMed ID: 34260894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate.
    Zhao Y; Hu ZY
    Br J Pharmacol; 2014 Feb; 171(4):1043-53. PubMed ID: 24283665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults.
    Sia JEV; Lai X; Wu X; Zhang F; Li H; Cui C; Liu D
    Eur J Pharm Sci; 2023 Mar; 182():106376. PubMed ID: 36626944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins.
    Shen H; Yao M; Sinz M; Marathe P; Rodrigues AD; Zhu M
    Mol Pharm; 2019 Sep; 16(9):4065-4076. PubMed ID: 31335150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan-induced gastrointestinal damage impairs the absorption of dabigatran etexilate.
    Hattori T; Imaoka A; Akiyoshi T; Ohtani H
    Biopharm Drug Dispos; 2019 Nov; 40(9):315-324. PubMed ID: 31642538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicted effect of ticagrelor on the pharmacokinetics of dabigatran etexilate using physiologically based pharmacokinetic modeling.
    Wang N; Chen L; Li N; Xu G; Qi F; Zhu L; Liu W
    Sci Rep; 2020 Jun; 10(1):9717. PubMed ID: 32546773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Aging-Related Function Variations of P-gp Transporter in Old-Elderly Chinese CHF Patients Based on Modeling and Simulation.
    Cui C; Qu Y; Sia JEV; Zhu Z; Wang Y; Ling J; Li H; Jiang Y; Pan J; Liu D
    Clin Pharmacokinet; 2022 Dec; 61(12):1789-1800. PubMed ID: 36378486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
    Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
    Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro predictability of drug-drug interaction likelihood of P-glycoprotein-mediated efflux of dabigatran etexilate based on [I]2/IC50 threshold.
    Kishimoto W; Ishiguro N; Ludwig-Schwellinger E; Ebner T; Schaefer O
    Drug Metab Dispos; 2014 Feb; 42(2):257-63. PubMed ID: 24212378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.
    Otsuka Y; Poondru S; Bonate PL; Rose RH; Jamei M; Ushigome F; Minematsu T
    J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):365-376. PubMed ID: 37344637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender.
    Shi J; Wang X; Nguyen JH; Bleske BE; Liang Y; Liu L; Zhu HJ
    Biochem Pharmacol; 2016 Nov; 119():76-84. PubMed ID: 27614009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing Potential Drug-Drug Interactions Between Dabigatran Etexilate and a P-Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling.
    Doki K; Neuhoff S; Rostami-Hodjegan A; Homma M
    CPT Pharmacometrics Syst Pharmacol; 2019 Feb; 8(2):118-126. PubMed ID: 30659778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis.
    Laizure SC; Parker RB; Herring VL; Hu ZY
    Drug Metab Dispos; 2014 Feb; 42(2):201-6. PubMed ID: 24212379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
    Yamazaki S; Loi CM; Kimoto E; Costales C; Varma MV
    Drug Metab Dispos; 2018 Aug; 46(8):1200-1211. PubMed ID: 29739809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.